For example, ARHGAP26 expression is significantly reduced in acute myeloid leukemia (AML) [3], chronic myeloid leukemia (CML) [3, 4], and ovarian cancer [5], while the transcription factor activity of ARHGAP26 is significantly increased and expression of ARHGAP26 is upregulated in prostate cancer [6]. This evidence concerns the gene ARHGAP26 and chronic myelogenous leukemia, BCR-ABL1 positive.